Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Gene-based Therapy
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : BGF
Deal Size : $16.0 million
Deal Type : Financing
Shift Bioscience Raises $16M to Advance Cell Simulation AI Platform
Details : The proceeds will be used for Shift Bioscience’s AI cell simulation platform, for the identification of genes that can safely rejuvenate cells to combat the effects of age-related illnesses.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 15, 2024
Lead Product(s) : Gene-based Therapy
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : BGF
Deal Size : $16.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?